Inflammatory response to percutaneous coronary intervention in stable coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 1, 2011, Pages 92-98

  Munk, Peter S ^a,b   Breland, Unni M ^c,d   Aukrust, Pål ^c,d   Skadberg, Oyvind ^a   Ueland, Thor ^c,d   Larsen, Alf I ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coronary artery disease; Cytokines; Inflammation; Percutaneous coronary intervention

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CXCL16 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN RECEPTOR ANTAGONIST; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN; PADGEM PROTEIN; PENTRAXIN 3; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BARE METAL STENT; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOPLASTY; C-REACTIVE PROTEIN; CD40 LIGAND; CORONARY ARTERY DISEASE; CYTOKINES; DRUG-ELUTING STENTS; E-SELECTIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; P-SELECTIN; SERUM AMYLOID P-COMPONENT; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78651490678     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0471-7     Document Type: Article

References (26)

1. N Saleh P Tornvall 2007 Serum c-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis Atherosclerosis 195 374 378 1:CAS:528:DC%2BD2sXhtlahtbzO 10.1016/j.atherosclerosis.2006.10.026 17126343
2. N Saleh B Svane LO Hansson J Jensen T Nilsson O Danielsson P Tornvall 2005 Response of serum c-reactive protein to percutaneous coronary intervention has prognostic value Clin Chem 51 2124 2130 1:CAS:528:DC%2BD2MXhtFyht7bN 10.1373/clinchem.2005.048082 16166173
3. M Almagor A Keren S Banai 2003 Increased c-reactive protein level after coronary stent implantation in patients with stable coronary artery disease Am Heart J 145 248 253 1:CAS:528:DC%2BD3sXjtVartrw%3D 10.1067/mhj.2003.16 12595841
4. J Karha AA Bavry V Rajagopal MR Henderson SG Ellis SJ Brener 2006 Relation of c-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent Am J Cardiol 98 616 618 1:CAS:528:DC%2BD28XotlKgurk%3D 10.1016/j.amjcard.2006.03.039 16923447
5. O Gach V Legrand Y Biessaux JP Chapelle S Vanbelle LA Pierard 2007 Long-term prognostic significance of high-sensitivity c-reactive protein before and after coronary angioplasty in patients with stable angina pectoris Am J Cardiol 99 31 35 1:CAS:528:DC%2BD2sXhsFGqsA%3D%3D 10.1016/j.amjcard.2006.07.059 17196457
6. AW Bonz B Lengenfelder M Jacobs J Strotmann S Held G Ertl W Voelker 2003 Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein iib/iiia receptor antagonism Am Heart J 145 693 699 1:CAS:528:DC%2BD3sXivV2nt7w%3D 10.1067/mhj.2003.65 12679767
7. BK Spencer III SC Smith Jr 2008 Updated guidelines for percutaneous coronary intervention: what are the most important changes? Pol Arch Med Wewn 118 96 97
8. J Bollerslev T Ueland AP Jorgensen KJ Fougner R Wergeland T Schreiner P Burman 2006 Positive effects of a physiological dose of gh on markers of atherogenesis: a placebo-controlled study in patients with adult-onset gh deficiency Eur J Endocrinol 154 537 543 1:CAS:528:DC%2BD28XktVCnsrc%3D 10.1530/eje.1.02125 16556716
9. N Kotooka T Inoue D Fujimatsu T Morooka S Hashimoto Y Hikichi T Uchida A Sugiyama K Node 2008 Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening Atherosclerosis 197 368 374 1:CAS:528: DC%2BD1cXisVSlsLk%3D 10.1016/j.atherosclerosis.2007.05.031 17640648
10. JP Casas T Shah AD Hingorani J Danesh MB Pepys 2008 C-reactive protein and coronary heart disease: a critical review J Intern Med 264 295 314 1:CAS:528:DC%2BD1cXht1Omt7%2FJ 10.1111/j.1365-2796.2008.02015.x 18823504
11. A Savchenko M Imamura R Ohashi S Jiang T Kawasaki G Hasegawa I Emura H Iwanari M Sagara T Tanaka T Hamakubo T Kodama M Naito 2008 Expression of pentraxin 3 (ptx3) in human atherosclerotic lesions J Pathol 215 48 55 1:CAS:528:DC%2BD1cXmtFKku7c%3D 10.1002/path.2314 18220316
12. B Bottazzi C Garlanda G Salvatori P Jeannin A Manfredi A Mantovani 2006 Pentraxins as a key component of innate immunity Curr Opin Immunol 18 10 15 1:CAS:528:DC%2BD28XhvFOhtg%3D%3D 10.1016/j.coi.2005.11.009 16343883
13. S Jaillon G Peri Y Delneste I Fremaux A Doni F Moalli C Garlanda L Romani H Gascan S Bellocchio S Bozza MA Cassatella P Jeannin A Mantovani 2007 The humoral pattern recognition receptor ptx3 is stored in neutrophil granules and localizes in extracellular traps J Exp Med 204 793 804 1:CAS:528: DC%2BD2sXksFSqur0%3D 10.1084/jem.20061301 17389238
14. GD Norata P Marchesi A Pirillo P Uboldi G Chiesa V Maina C Garlanda A Mantovani AL Catapano 2008 Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells Arterioscler Thromb Vasc Biol 28 925 931 1:CAS:528:DC%2BD1cXktlymu74%3D 10.1161/ATVBAHA.107. 160606 18218986
15. I Seljeflot S Tonstad I Hjermann H Arnesen 2002 Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease Atherosclerosis 162 179 185 1:CAS:528:DC%2BD38Xis1eit70%3D 10.1016/S0021-9150(01)00696-7 11947912
16. UM Breland B Halvorsen J Hol E Oie G Paulsson-Berne A Yndestad C Smith K Otterdal U Hedin T Waehre WJ Sandberg SS Froland G Haraldsen L Gullestad JK Damas GK Hansson P Aukrust 2008 A potential role of the cxc chemokine groalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins Arterioscler Thromb Vasc Biol 28 1005 1011 1:CAS:528:DC%2BD1cXktlymu7s%3D 10.1161/ATVBAHA.108.162305 18276907
17. F Parhami ZT Fang AM Fogelman A Andalibi MC Territo JA Berliner 1993 Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate J Clin Invest 92 471 478 1:CAS:528:DyaK3sXmt1Cjsbc%3D 10.1172/JCI116590 8392092
18. BV Khan SS Parthasarathy RW Alexander RM Medford 1995 Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells J Clin Invest 95 1262 1270 1:CAS:528:DyaK2MXktlKhu78%3D 10.1172/JCI117776 7533787
19. L Nannizzi-Alaimo VL Alves DR Phillips 2003 Inhibitory effects of glycoprotein iib/iiia antagonists and aspirin on the release of soluble cd40 ligand during platelet stimulation Circulation 107 1123 1128 1:CAS:528:DC%2BD3sXhsVWru7k%3D 10.1161/01.CIR.0000053559.46158.AD 12615789
20. P Aukrust JK Damas NO Solum 2004 Soluble cd40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol 43 2326 2328 1:CAS:528:DC%2BD2cXmt1Ggu7g%3D 10.1016/j.jacc.2004.03.023 15193701
21. P Aukrust F Muller T Ueland T Berget E Aaser A Brunsvig NO Solum K Forfang SS Froland L Gullestad 1999 Enhanced levels of soluble and membrane-bound cd40 ligand in patients with unstable angina. Possible reflection of t lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 614 620 1:STN:280:DyaK1MzmvFOrtg%3D%3D 10441098
22. O Dormond AG Contreras E Meijer D Datta E Flynn S Pal DM Briscoe 2008 Cd40-induced signaling in human endothelial cells results in mtorc2- and akt-dependent expression of vascular endothelial growth factor in vitro and in vivo J Immunol 181 8088 8095 1:CAS:528:DC%2BD1cXhtl2gsL3E 19018001
23. K Otterdal TM Pedersen NO Solum 2004 Release of soluble cd40 ligand after platelet activation: studies on the solubilization phase Thromb Res 114 167 177 1:CAS:528:DC%2BD2cXntlGnsr8%3D 15342213
24. A Zernecke E Shagdarsuren C Weber 2008 Chemokines in atherosclerosis: an update Arterioscler Thromb Vasc Biol 28 1897 1908 1:CAS:528:DC%2BD1cXht1Ggtb%2FL 10.1161/ATVBAHA.107.161174 18566299
25. JK Damas C Smith E Oie B Fevang B Halvorsen T Waehre A Boullier U Breland A Yndestad O Ovchinnikova AK Robertson WJ Sandberg J Kjekshus K Tasken SS Froland L Gullestad GK Hansson O Quehenberger P Aukrust 2007 Enhanced expression of the homeostatic chemokines ccl19 and ccl21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization Arterioscler Thromb Vasc Biol 27 614 620 1:CAS:528:DC%2BD2sXhsVSit7s%3D 10.1161/01.ATV. 0000255581.38523.7c 17170367
26. JS Lee MM Wurfel G Matute-Bello CW Frevert MR Rosengart M Ranganathan VW Wong T Holden S Sutlief A Richmond S Peiper TR Martin 2006 The duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation J Immunol 177 8086 8094 1:CAS:528: DC%2BD28Xht1WrsLjO 17114483